Abstract: Provided herein is a 7-genes signature, an algorithm to evaluate a patient's risk score, and methods of use thereof. The methods provided herein include methods of use of a risk score to predict lung cancer patient survival and lung cancer patient likelihood to respond to adjuvant chemotherapy.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: Implementations discussed and claimed herein provide systems and methods for characterizing patient tissue of a patient. In one implementation, a pathological image of the patient tissue is received. Nuclei of the plurality of cells in the pathological image are simultaneously segmented and classified using a histology-based digital staining system. The nuclei of the plurality of cells are segmented according to spatial location and classified according to cell type, thereby generating one or more groups of nuclei. Each of the one or more groups of nuclei have an identified cell type. A composition and a spatial organization of a tumor microenvironment of the patient tissue is determined based on the one or more groups of nuclei. A prognostic model for the patient is generated based on the composition and the spatial organization of the tumor microenvironment.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, ?-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected measuring a level of four or more biomarkers selected from ILL IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, and ?-synuclein, A?40, A?42, tau, ?-synuclein, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, ?-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: The present invention is drawn to methods of predicting prognosis of, and therapeutic response in, carcinoma of the lung.

Abstract: Methods and devices for predicting, diagnosing, monitoring, or determining Alzheimer's disease in a human are described. In particular, methods and devices for predicting diagnosing, monitoring, or determining AD using measured concentrations of a combination of three or more analytes in a test sample taken from the human are described.